New Research on Magrolimab Provides Key Insights as Gilead Rapidly Expands Research in AML
Former TAP Partner
FOSTER CITY, Calif. & SANTA MONICA, Calif. November 04, 2021 --(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that data at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (December 11-14) will showcase early-stage research on magrolimab, an investigational CD47 inhibitor, both in an oral session and in an ASH-EHA Joint Symposium. In addition, four trials in progress will be on display highlighting ongoing clinical trials of magrolimab in myeloma, AML and MDS. Gilead acquired Forty Seven back in 2020 and is continuing development of magrolimab in multiple blood cancer indications.
|
Investigator-Sponsored Research (ISR) Oral Presentation |
|
|
Acute Myeloid Leukemia Abstract #371 Sunday, Dec 12 |
Phase I/II Study of Azacitidine with Venetoclax and Magrolimab in Patients with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory AML |
|
Trials-In-Progress (TiP) |
|
|
Multiple Myeloma Abstract #2757 Sunday, Dec 12 |
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma |
|
Acute Myeloid Leukemia Abstract #3424 Monday, Dec 13 |
A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia |
|
Acute Myeloid Leukemia Abstract #3426 Monday Dec 13 |
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia |
|
Myelodysplastic Syndrome Abstract #3706 Monday, Dec 13 |
Magrolimab + Azacitidine versus Azacitidine + Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndrome (MDS): The Phase 3 Randomized, ENHANCE Study |